Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians with Dialysis Patients that use the NxStage System One

Articles with lock require a subscription to GLG News | Request a free trial
August 4, 2008
FDA Restrictions on ESA's Will Have Minimal Effect of EPO Usage.
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
1)  Concerns over the new FDA restrictions on ESA's is being overstated. 2)  Amgen will continue to do well in the ESA market place, in spite of these changes. 3)  J&J will receive the brunt of these changes, strictly because of their market concentration in the oncology market. 4) ...
August 4, 2008
Veterans Admininstration Sets The Standard for Electronic Medical Records: Why Re-invent The Wheel?
Analysis of: Nationwide EHR Implementation Price Tag Estimated at $150 billion | www.govhealthit.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
The VA has already won many awards for an electronic medical records system, which tax payers have already paid for. Adopting the VA "CPRS" program would save the taxpayers and the private sector hundreds of billions of dollars.
April 30, 2008
FDA: Chinese Manufacturer of Tainted Heparin Involved in Fraud.
Analysis of: UPDATE: FDA Head Sees Economic Fraud Behind Tainted Heparin | www.reuters.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
First, and foremost, the only working link for this article can be found at: http://www.reuters.com/article/domesticNews/idUSWAT00934620080415?feedType=RSS&feedName=domesticNews Although there is no proof offered in the article to substantiate the suggestion of fraud, there is enough circumstantial...
April 30, 2008
FDA Fees Must Be Increased to Fund Inspection of Chinese Products.
Analysis of: FDA fees eyed to boost food, drug safety | www.usatoday.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
One only has to read about the Heparin debacle, which has killed, at least, 81 Americans, to realize that there is a serious issue with the quality of medicines produced in China.  Manufacturing of medical food and consumer goods in China is growing at such a rate, the Chinese government has neither...
April 30, 2008
Who to Blame for Waste in the Medical Industry? Who's on First?
Analysis of: The Price of Excess: Identifying Waste in Healthcare Spending | blogs.wsj.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent...
April 30, 2008
Anemia Drugs Have Been Abused for Profit!
Analysis of: WellPoint likely to follow FDA on anemia drugs | www.reuters.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
Over the last year, it has become clear that the over-use of anemia drugs for cancer and renal failure has become a problem.  The reason can be sumed up in one word, which is profit.
March 24, 2008
Base Product in Baxter's Heparin Came from China!
Analysis of: Tainted Blood Drug to Face Import Tests | www.nytimes.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
1)  Baxter was producing 50% of the worlds heparin requirements, which provided short term anticoagulation for hemodialysis and various interventions for cardiovascular disease. 2)  The base product of heparin comes from porcine intestines. 3)  The base product of Baxter's heparin was...
March 24, 2008
Amgen Stock Set to Take a Fall!
Analysis of: Panel Seeks New Limits on Anemia Drugs | www.nytimes.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
1)  Amgen's and J&J's ESA products are going to continue to receive more black box warnings from the FDA. 2)  A federal Judge may force Amgen to accept a royalty from Roche, allowing their CERA ESA to come to market in the USA. 3)  Their is potential for more problems to arise,...
February 19, 2008
Chinese Heparin Debacle May Cause World Wide Shortage for Dialysis Providers
Analysis of: China Plant Played Role | online.wsj.com
Author: Joe Atkins, Chief Executive Officer, Medical Concepts & Innovations
Although patient deaths are of grave concern, the impact of a heparin shortage stand to put around 400,000 US dialysis patients at risk.  Heparin is the "oil of hemodialysis" and without it, hemodialysis would come to a standstill. There are alternatives available, such as Andiomax and Lovenox,...
September 10, 2007
Laropiprant no better than aspirin? or is it?!
Analysis of: Merck 'good' cholesterol drug meets trial goals | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Extended Release niacin has the second highest discontinuation rate.   Laropiprant is a selective antagonist of the prostaglandin D(2) receptor subtype 1, which reduces niacin-induced vasodilation. Is it better than Aspirin?! 

Page : 1 2 3 Next1 to 10 of 21

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637